We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+13.81%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.53B
AUM Growth
+$567M
Cap. Flow
+$2.93M
Cap. Flow %
0.04%
Top 10 Hldgs %
36.11%
Holding
184
New
8
Increased
71
Reduced
51
Closed
13

Top Buys

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$20.9M
2
INCY icon
Incyte
INCY
+$16.3M
3
ISRG icon
Intuitive Surgical
ISRG
+$14.4M
4
DXCM icon
DexCom
DXCM
+$14.1M
5
CNC icon
Centene
CNC
+$13.5M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$40.9M
2
UNH icon
UnitedHealth
UNH
+$38.4M
3
ELV icon
Elevance Health
ELV
+$26.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$24M
5
AXNX
Axonics, Inc. Common Stock
AXNX
+$19M

Sector Composition

Rank Sector Weight
1 Healthcare 99.55%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMCL icon
76
Omnicell
OMCL
$2.08B
$26.1M 0.35%
518,384
+104,100
+25% +$6.25M
MRSN
77
DELISTED
Mersana Therapeutics
MRSN
$25.1M 0.33%
171,304
+8,000
+5% +$1.35M
ADPT icon
78
Adaptive Biotechnologies
ADPT
$3.49B
$22.6M 0.3%
2,960,131
-319,489
-10% -$2.49M
CSTL icon
79
Castle Biosciences
CSTL
$723M
$22.2M 0.3%
944,312
+2,441
+0.3% +$56.6K
PHR icon
80
Phreesia
PHR
$651M
$21.6M 0.29%
666,419
– –
KZR
81
DELISTED
Kezar Life Sciences
KZR
$21.3M 0.28%
303,100
– –
PRVA icon
82
Privia Health
PRVA
$3.34B
$20.5M 0.27%
900,666
+385,636
+75% +$10.7M
RMD icon
83
ResMed
RMD
$28.4B
$20.5M 0.27%
98,275
+13,663
+16% +$3M
EPIX
84
DELISTED
ESSA Pharma
EPIX
$19.9M 0.26%
7,898,583
+2,000,000
+34% +$5.74M
SRRK icon
85
Scholar Rock
SRRK
$6.24B
$19.5M 0.26%
2,152,025
– –
ILMN icon
86
Illumina
ILMN
$27.9B
$19.2M 0.25%
97,564
+9,231
+10% +$1.91M
CVS icon
87
CVS Health
CVS
$138B
$19M 0.25%
204,205
-20,909
-9% -$2.02M
HOLX
88
DELISTED
Hologic
HOLX
$18.2M 0.24%
243,171
-8,241
-3% -$587K
LEGN icon
89
Legend Biotech
LEGN
$4.44B
$17.7M 0.24%
354,789
-270,672
-43% -$13.1M
ALGN icon
90
Align Technology
ALGN
$12.5B
$16.7M 0.22%
79,194
+4,255
+6% +$852K
BAX icon
91
Baxter International
BAX
$11.4B
$16.3M 0.22%
320,681
+1,133
+0.4% +$60.9K
DOCS icon
92
Doximity
DOCS
$3.84B
$15.1M 0.2%
448,579
+255,140
+132% +$7.79M
GBIO
93
DELISTED
Generation Bio
GBIO
$14.3M 0.19%
362,728
– –
TXG icon
94
10x Genomics
TXG
$5.4B
$11.8M 0.16%
324,746
+70,612
+28% +$2.31M
REGN icon
95
Regeneron Pharmaceuticals
REGN
$70.7B
$11.3M 0.15%
15,678
-1,711
-10% -$1.26M
GILD icon
96
Gilead Sciences
GILD
$166B
$11.2M 0.15%
130,343
+32,489
+33% +$2.57M
NVRO
97
DELISTED
NEVRO CORP.
NVRO
$10.3M 0.14%
260,835
– –
AMGN icon
98
Amgen
AMGN
$198B
$10.2M 0.14%
38,939
-6,257
-14% -$1.68M
AVTR icon
99
Avantor
AVTR
$7.31B
$9.95M 0.13%
471,621
-31,386
-6% -$650K
BDTX icon
100
Black Diamond Therapeutics
BDTX
$101M
$9.72M 0.13%
5,400,839
+683,726
+14% +$1.23M
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2022 Portfolio in Review

As of Q4 2022, Bellevue Group held 184 positions worth $7.53B, up 8.1% from $6.97B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Bellevue Group's Q4 2022 filing shows 8 new, 71 increased, 51 reduced and 13 closed positions. Its largest new stake was Natera: 173,812 shares worth $6.98M. The largest sale was Abiomed Inc, an estimated $40.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q4 2022 buy was Natera: 173,812 shares worth $6.98M.
  • Bellevue Group added most to Fate Therapeutics in Q4 2022, an estimated $20.9M increase.
  • Bellevue Group's biggest Q4 2022 reduction was UnitedHealth, cutting an estimated $38.4M.
  • Bellevue Group fully exited Abiomed Inc in Q4 2022, selling an estimated $40.9M.
  • Bellevue Group's ten largest holdings make up 36% of its $7.53B portfolio in Q4 2022.
  • Bellevue Group opened 8 new positions and closed 13 in Q4 2022.
  • Bellevue Group's portfolio value rose 8.1% quarter-over-quarter to $7.53B.

Based on Bellevue Group's 13F filing for Q4 2022, filed 14 Feb 2023.